



### MLLT1 Antibody (C-term) Blocking Peptide

Synthetic peptide Catalog # BP6188a

#### **Specification**

MLLT1 Antibody (C-term) Blocking Peptide - Product Information

Primary Accession 003111 Other Accession NP 005925

MLLT1 Antibody (C-term) Blocking Peptide - Additional Information

**Gene ID 4298** 

#### **Other Names**

Protein ENL, YEATS domain-containing protein 1, MLLT1, ENL, LTG19, YEATS1

#### Target/Specificity

The synthetic peptide sequence used to generate the antibody <a href=/product/pr oducts/AP6188a>AP6188a</a> was selected from the C-term region of human MLLT1 . A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

#### **Format**

Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

#### Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

#### **Precautions**

This product is for research use only. Not for use in diagnostic or therapeutic procedures.

MLLT1 Antibody (C-term) Blocking Peptide - Protein Information

Name MLLT1

# MLLT1 Antibody (C-term) Blocking Peptide - Background

Chromosome band 11q23 is the site of translocations in myeloid and lymphoid acute leukemias, pediatric leukemias, and treatment-induced secondary acute myelogenous leukemia. The translocation breakpoints cluster in a restricted region of the HRX gene resulting in chimeric genes that encode an N-terminal portion of Hrx fused to various partner proteins. Myeloid/lymphoid or mixed-lineage leukemia translocated to 1 (MLLT1) is a nuclear protein with transcriptional transactivation properties that is fused to Hrx in t(11;19) leukemias. The minimal MLLT1 sequence required for transcription activation was narrowed to the C-terminal 90 amino acids.

### MLLT1 Antibody (C-term) Blocking Peptide - References

Nie, Z., et al., Mol. Cell. Biol. 23(8):2942-2952 (2003).Lavau, C., et al., Proc. Natl. Acad. Sci. U.S.A. 97(20):10984-10989 (2000).Thirman, M.J., et al., Proc. Natl. Acad. Sci. U.S.A. 91(25):12110-12114 (1994).Rubnitz, J.E., et al., Blood 84(6):1747-1752 (1994).Yamamoto, K., et al., Oncogene 8(10):2617-2625 (1993).



#### Synonyms ENL, LTG19, YEATS1

#### **Function**

Chromatin reader component of the super elongation complex (SEC), a complex required to increase the catalytic rate of RNA polymerase II transcription by suppressing transient pausing by the polymerase at multiple sites along the DNA (PubMed:<a href="http://www.uniprot.org/c itations/20159561" target=" blank">20159561</a>, PubMed:<a href="http://www.uniprot.org/ci tations/20471948" target=" blank">20471948</a>). Specifically recognizes and binds acetylated and crotonylated histones, with a preference for histones that are crotonylated (PubMed:<a href="http://www. uniprot.org/citations/27105114" target=" blank">27105114</a>). Has a slightly higher affinity for binding histone H3 crotonylated at 'Lys-27' (H3K27cr) than 'Lys-20' (H3K9cr20) (PubMed:<a href="http ://www.uniprot.org/citations/27105114" target=" blank">27105114</a>).

**Cellular Location** Nucleus.

## MLLT1 Antibody (C-term) Blocking Peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

• Blocking Peptides